anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present study aimed to compare the prevalence of oral problems between individuals with rare genetic diseases that affect skeletal development and individuals without rare diseases. A cross-sectional study was conducted with 210 individuals between two and fifty-four years of age: 105 with rare genetic diseases (27 with mucopolysaccharidosis [MPS] and 78 with osteogenesis imperfecta [OI]) and 105 without rare diseases. The rare genetic disease group was recruited from hospital units that provide care for patients with MPS and OI in five states of Brazil, and the other group was recruited from the same location. The participants were examined with regards to malocclusion, dental anomalies, dental caries, and gingivitis. A questionnaire was administered addressing individual, sociodemographic, and behavioral characteristics as well as dental history. A descriptive analysis was performed, followed by unadjusted and adjusted binary logistic regression analyses. The mean age was 14.1 ± 12.2 years. Individuals with a rare disease were 12.9-fold more likely to have some type of oral problem (95% CI: 3.7-44.7) compared to the group without rare diseases. The prevalence of oral problems was higher among Brazilians with MPS and OI compared to normotypical individuals.
For treatment interventions to provide the desired result of long term abstinence, it is important to develop strategies to enhance the effectiveness of continued care approaches. We plan to conduct a prospective, randomized comparison of four models of counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program. Some 500 participants completing a 4-month Matrix Outpatient Model of stimulant abuse treatment will be randomly assigned to one of four counseling groups (n=100 per group): (1) unstructured/non-directive, (2) structured/non-directive, (3) unstructured/directive, or (4) structured/directive telephone counseling, or (5) a control group consisting of standard referral to Matrix aftercare, for a total sample size of 500. The two structured conditions will be based on the behavioral "prompts" identified by Farabee et al. (2002)\* as being associated with drug avoidance. In the non-directive conditions, subjects will be allowed to state their own goals and how they intend to achieve them. In the directive conditions, the counselor will provide specific recommendations to help the subject adopt as many of the drug-avoidance activities as possible. Outcomes will be tracked for 12 months following completion of primary treatment (a total of 16 months after treatment admission) and will include measurement of participation in drug-avoidance activities (including aftercare participation) as well as self-reported and objective measures of substance use and related behavior change.

\*Farabee, D., Rawson, R.A., \& McCann, M. (2002). Adoption of drug avoidance activities among patients in contingency management and cognitive-behavioral treatments. Journal of Substance Abuse Treatment, 23, 343-350.
Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
The trial has randomized 12,705 women 60 years or older and men 55 years or older without known heart disease or prior stroke and without a clear indication or contraindication to any of the study medications. Eligible and consenting individuals were randomized to receive either active study medications or placebo (dummy pills) and will be monitored for an average of 5.7 years. The rates of heart attacks, strokes, deaths and other cardiovascular events will be compared between subjects receiving the active drugs and those on placebo. The study included people from 21 countries, which were monitored by an international group of scientists and physicians. The study was coordinated by the Population Health Research Institute at McMaster University. The study is expected to demonstrate that combined lipid lowering and blood pressure lowering will substantially lower the risk for cardiovascular diseases and may substantially change our approach to cardiovascular prevention.
In hypertrophic scars, the differentiation and migration of fibroblasts are influenced by the extracellular matrix microenvironment, which includes factors such as stiffness, restraint, and tensile force. These mechanical stresses incite alterations in cell behavior, accompanied by cytoskeletal protein reorganization. However, the role of nucleo-skeletal proteins in this context remains underexplored. In this study, we use a polyacrylamide hydrogel (PAA) to simulate the mechanical stress experienced by cells in scar tissue and investigate the impact of Emerin on cell behavior. We utilize atomic force microscopy (AFM) and RNA interference technology to analyze cell differentiation, migration, and stiffness. Our findings reveal that rigid substrates and cellular restriction elevate Emerin expression and diminish differentiation. Conversely, reducing Emerin expression leads to attenuated cell differentiation, where stiffness and constraining factors exert no notable influence. Furthermore, a softening of cells and an enhanced migration rate are also markedly observed. These observations indicate that variations in nuclear skeletal proteins, prompted by diverse matrix microenvironments, play a pivotal role in the pathogenesis of hypertrophic scars (HSs). This research offers novel insights and a reference point for understanding scar fibrosis formation mechanisms and preventing fibrosis.
PURPOSE: To heighten the effect of cosmetic treatment applied to a bleached hair by irradiating laser light beam to the bleached hair. CONSTITUTION: A part of plural locks of hair to be treated is irradiated by using a laser light beam discharged in a pulse state to degrade melanin in the hair and to bleach. If necessary, the locks of the hair are successively treated by relatively moving the locks to the laser light beam. The laser light having an output capable of transmitting 0.1-1.2 J/cm<2> energy density per pulse at 532 nm is used, and the energy density has a value not larger than the threshold damaging a keratin fiber of the hair and the threshold is set lower according to the color becomes darker. The method provides smaller bad effect to hair mechanical and physicochemical properties compared with the bleaching method by a chemical means. The cosmetic treatment applied to the hair bleached by the method manifests an excellent effect especially on a permanent wave treatment.
Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
NEW MATERIAL:3,4-Dihydro-2H-thiopyran-3-one derivatives of formulas I and II : (R1, R2,R3, and R4 are H or lower alkyl groups). EXAMPLE:2-Methyl-3,4-dihydro-2H-thiopyran-3-one. USE:Anti-inflammatory drugs, diuretics and intermediates for them. PROCESS:2-Allylmercaptoacetic acid chlorides of formula III are subjected to internal cyclization in an organic solvent, e.g. tetrachloro-ethane, etc. in the presence of anhydrous aluminum chloride catalyst at about 50 deg.C under heating for about 2 hr to give 3,4-dihydro-2H-thiopyran-3-one derivatives of formulas I and/or II. The starting compounds of formula III can be prepared by reacting compounds of formula IV with compounds of formula V in an aqueous sodium hydroxide to form reaction products, which are treated with thionyl chloride.
The invention discloses a hawthorne leaf total-flavones sustained-release preparation and a preparation method thereof. The hawthorne leaf total-flavones sustained-release preparation comprises a fast-release component and a sustained-release component according to a weight part ratio of 1: (1-4). The fast-release component contains hawthorne leaf total-flavones of which the weight is 2.4-9.6% of the weight of the hawthorne leaf total-flavones sustained-release preparation. The sustained-release component contains hawthorne leaf total-flavones of which the weight is 7.2-16% of the weight of the hawthorne leaf total-flavones sustained-release preparation. The fast-release component can fast release drugs in an earlier stage after drug administration, fast relieve clinical symptoms of patients, and timely reduce patient pain. The sustained-release component can slowly release drugs in a later stage after drug administration, guarantee balanced and lasting effects, solve the problem that the common preparation has high drug administration frequency and causes a large change of a plasma concentration, improve patient compliance, and is conducive to use for a long time. The hawthorne leaf total-flavones sustained-release preparation has a fast drug release rate in the earlier stage thereby improving an initial concentration, has an obvious sustained-release effects in the later stage, and has the advantages of fast onset and stable and lasting effects.
Typhoid fever is caused by Salmonella typhi and Salmonella paratyphi. It is a disease of developing countries and is seen among people of low socio-economic status. Patients can develop complications like typhoid intestinal perforation which is associated with higher mortality. A 15-year-old female presented to the emergency pediatric unit with fever, abdominal pain and abdominal distension. She was septic, in respiratory distress, and had marked generalized abdominal tenderness with guarding. An assessment of generalized peritonitis secondary to typhoid intestinal perforation was made. She had exploratory laparotomy with intra-operative findings of ileal perforation and gastric perforation. She had repair of the intestinal and gastric perforations. Our patient presented late with concurrent use of NSAIDs and overwhelming sepsis which likely contributed to the gastric perforation as this is not a usual finding in patients with typhoid intestinal perforation. Gastric perforation is an unusual finding in patients with typhoid intestinal perforation. Typhoid fever and its complications can be easily prevented by the provision of safe water, proper facilities for sanitation, and practicing good hygiene.
To assess the influence of physical training on neuronal activation and hypothalamic expression of vasopressin and oxytocin in spontaneously hypertensive rats (SHR), untrained and trained normotensive rats and SHR were submitted to running until fatigue while internal body and tail temperatures were recorded. Hypothalamic c-Fos expression was evaluated in thermoregulatory centers such as the median preoptic nucleus (MnPO), medial preoptic nucleus (mPOA), paraventricular nucleus of the hypothalamus (PVN), and supraoptic nucleus (SON). The PVN and the SON were also investigated for vasopressin and oxytocin expressions. Although exercise training improved the workload performed by the animals, it was reduced in SHR and followed by increased internal body temperature due to tail vasodilation deficit. Physical training enhanced c-Fos expression in the MnPO, mPOA, and PVN of both strains, and these responses were attenuated in SHR. Vasopressin immunoreactivity in the PVN was also increased by physical training to a lesser extent in SHR. The already-reduced oxytocin expression in the PVN of SHR was increased in response to physical training. Within the SON, neuronal activation and the expressions of vasopressin and oxytocin were reduced by hypertension and unaffected by physical training. The data indicate that physical training counterbalances in part the negative effect of hypertension on hypothalamic neuronal activation elicited by exercise, as well as on the expression of vasopressin and oxytocin. These hypertension features seem to negatively influence the workload performed by SHR due to the hyperthermia derived from the inability of physical training to improve heat dissipation through skin vasodilation.
A self-ligating orthodontic bracket has a bonding base adapted for attachment to the crown of a tooth. A body member is attached to the front surface of the base and extends forwardly to a front face. The base defines a torque angle with respect to the front face of the body. Gingival and occlusal projections extend forwardly from the body member. The projections have archwire slot surfaces which, together with a portion of the body member's front face, define an archwire slot. First and second channels defined in the projections are coplanar and are disposed at an angle to the front face of the body member that is substantially equal to the torque angle. A door is disposed in one of the first and second channels. The door is movable between an open position and a closed position to selectably provide or prevent access to and from the archwire slot.
The present invention relates to medical differences of Nicandra Physaloides Seed in the north and in the south. The specific characteristics is a new discovery on the curing range that the single preparation can cure chronic nephritis and chronic renal failure and no similar reports are seen at home for years. In use, Nicandra Physaloides Seed in the north is applied to the preparation of medicine for curing chronic nephritis and chronic renal failure. The social and economic prospect of the present invention is good. The medicine also has a breakthrough of effectively controlling renal failure in the theory of disease development. In addition, the present invention has good curing effect, low expense and small side effect and obviously increases the living quality of patients, thus being easily accepted in use.
The primary purpose of this phase I study is to evaluate the safety of a skin engraftment procedure for transplanting ex-vivo transduced keratinocytes in patients with a deficiency of the ornithine transferase gene (OAT). The safety of this procedure will be evaluated in terms of technical complications and the immune response of the patient to the presence of the transduced keratinocytes. Adult patients with gyrate atrophy, a disease defined by a deficiency of OAT, who have been followed for an extended period of time at the National Eye Institute and whose natural history is known to the investigators will be evaluated for study enrollment. Keratinocytes, previously obtained and grown in culture from these patients, will be transduced with a retrovirus manufactured under GMP conditions to express the OAT gene. The autologous transduced keratinocytes will be returned to the patient on the upper thigh in a small patch prepared to receive graft. At study defined visits, the site integrity will be monitored and biopsies of the grafted areas will be performed. The biopsies will provide information to evaluate the following three secondary study objectives: 1) the ability of keratinocytes to express the OAT gene, 2) the extent and duration of such expression, and 3) the extent to which the activity present in the keratinocytes is sufficient to lower serum levels of ornithine.
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
FIELD: medicine. SUBSTANCE: the suggested device for percutaneous injection of active substances (I and II) contains two sections (A and B). Section A contains foundation including active substance I, section B contains foundation including active substance B. Both foundations are covered with protective films a and a′, correspondingly, which could be either similar or different by their nature. Active substance A is separated against active substance B with clearance of 1-10 mm width, and sections A and B are placed upon total protective film (b). The suggested device enables to inject every active substance by optimal way for medicinal preparation could pass percutaneously and for the purpose to avoid interaction of one compound with main substance of another compound. EFFECT: higher efficiency. 10 cl, 1 dwg, 1 tbl
Central Retinal Vein Occlusion (CRVO) is the second most frequently retinal vascular disease causing loss of vision, after diabetic retinopathy. No treatment of CRVO has clearly demonstrated beneficial and long lasting visual results. Commonly used treatment options are platelet anti-aggregating agents, correcting rheologic factors with troxerutin and isovolumic hemodilution. Surgical treatment of CRVO has recently been proposed (2001) and has been studied in numerous non comparative pilot studies. Limited but encouraging results motivate our randomised controlled trial. We will evaluate at 6 months visual acuity after surgery associating pars plana vitrectomy and radial optic neurotomy, in patients with central vein occlusion and bad vision, associated with the correction of rheologic factors.
PROBLEM TO BE SOLVED: To obtain a new compound having both high antifungal effect and safety, and useful as e.g. an agrochemical. SOLUTION: This new compound is shown by formula I ((m) is 0-17), pref. a compound of formula I ((n) is 0-17), e.g. N-butyl-3-hydroxypicolinic acid amide. It is preferable that this new compound is obtained, for example, by forming a mixed acid anhydride between (A) a dehydrocondensation reagent such as phosphorus trichloride or phosphorus oxychloride and (B) a carboxylic acid such as 3-hydroxypicolinic acid or 2-hydroxynicotinic acid to raise the reactivity of the system followed by reaction of the mixed acid anhydride with (C) a straight-chain alkylamine in an inert solvent such as tetrahydrofuran at -50 to 50 deg.C.
The present invention relates to the field of digital vaccination certificates. As indicated by the title of the invention, it covers in particular: digital vaccination certificates and methods for issuing, editing, displaying and checking digital vaccination certificates. It can be assumed that certain vaccinations lose their effectiveness as time passes and the protection provided by the vaccination decreases over time. After a certain amount of time has passed this can mean that people who have been vaccinated can no longer effectively ward off infection if they are exposed to a particular pathogen and become ill from the infection. Furthermore, as protection wanes, it also becomes more likely that the infection will be passed on to others. Both of these aspects play an absolutely critical role during pandemics, for example, where the spread among people and the spread of a particular pathogen has to be stopped as effectively as possible. In order to prevent a pandemic spreading or to prevent it re-emerging, the invention makes it possible for a digital vaccination certificate to also contain information on the time-related effectiveness of protection provided by the vaccination. It is thus made possible, with regard to digital vaccination certificates and methods, inter alia, to assign a time-related validity to digital vaccination certificates, which validity can be associated with ongoing effectiveness of protection over time. The invention also makes it possible to design vaccination certificates, including in methods, on a more individual basis and to select ongoing effectiveness over time by age, gender or medical history, for example, and to take this into account accordingly during checks.
A significant problem in drug development of novel small molecules is the lack of available tissues (surrogate tissues) that allow for the assessment of the molecular and biochemical effects of (targeted-therapies) drug action. The information obtained from surrogate tissues might help us validate previous preclinical studies with those agents and also dose them in a more rational way. Oral keratinocytes, which are accessible by non-invasive means, might be useful to assess drug action. The proposed study seeks to investigate the genetic, molecular, and biochemical effects of novel agents in oral buccal mucosal cells. Patients already enrolled in Phase I and II clinical trials for neoplastic diseases at the Clinical Center will undergo oral cytobrushing before and during therapy to determine the molecular and biochemical effects of novel agents in the oral mucosa cells. Similar studies will be performed in peripheral blood mononuclear cells. In order to validate to compare and compare the oral cytobrush methodology, some of these subjects will undergo oral punch biopsy studies. Some of these subjects will also undergo tumor biopsy, if accessible or available.
Cerebral palsy (CP) is primarily a neuromotor disorder that affects the development of movement, muscle tone and posture. The underlying pathophysiology is an injury to the developing brain in the prenatal through neonatal period. Although the initial neuropathologic lesion is non-progressive, children with CP may develop a range of secondary conditions over time that will variably affect their functional abilities.

Cerebral palsy refers to set of lifelong mobility issues and postural defects which restrict function caused by non-progressive abnormalities in growing foetus or neonatal brain. CP is frequently followed by sensory, cognitive, behavioural impairment and musculoskeletal difficulties. CP could categorised as spastic, athetoid, ataxic, or mixed, also classed as hemiplegia, diplegia, quadriplegia, depending on kind of mobility dysfunction. Spasticity of numerous muscle groups is common in CP due to CNS injury
This is an exploratory Phase 2, single site, open-label, direct-to-family, adherence and exposure-response study of hydroxychloroquine (HCQ) in pediatric systemic lupus. The study will measure a participant's adherence to HCQ self-administration using an electronic pill bottle cap that records date/time of bottle opening and provides participants with a reminder when a dosage is due and/or missed. All participants will be provided with the electronic pill bottle cap to use with their regular HCQ prescription at the start of the study. For the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls). Participants will continue to receive notifications via the electronic pill bottle cap through Visit 4. Throughout the study, participants will undergo a series of blood draws and urinalysis collections, and be asked to complete various questionnaires.